重组人促红细胞生成素治疗结肠和直肠癌化疗相关贫血

Recombinant human erythropoietin therapy for anemia associated with chemotherapy in colorectal carcinoma patients

目的 :观察重组人促红细胞生成素 (rhEPO)治疗结、直肠癌化疗相关贫血的疗效。方法 :选择 6 2例结、直肠癌采用以奥沙利铂为主联合方案化疗所致贫血患者 ,随机分为两组 :rhEPO治疗组 34例 ,给予皮下注射rhEPO 4 0 0 0 0U/周。对照组 2 8例 ,不给予rhEPO治疗 ,仅给予五参芪口服液。结果 :治疗后 4周起治疗组患者血红蛋白 (Hb) ,红细胞压积 (HCT)、红细胞总数 (RBC)均明显上升 ,与对照组相比差异有统计学意义 (P <0 .0 1)。rhEPO治疗组总有效率为 79.4 % ,对照组为 2 1.7% ,差异有统计学意义 (P <0 .0 1)。结论 :rhEPO 4 0 0 0 0U/周对晚期结。

Objective:To investigate the effect of recombinant human erythropoietin (rhEPO) therapy for anemia associated with chemotherapy in colorectal carcinoma patients.Method:62 colorectal cancer patients with anemia associated with chemotherapy were divided into two groups at random: one was with rhEPO(40 000 u/w), including 34 patients; another was without rhEPO.Result:4 weeks after therapy, Hb, HCT, RBC of the rhEPO treatment group were significantly higher than that of the control(P< 0.01). The overall response rate of the rhEPO treatment group was 79.4% which was significantly higher than that of the control( 21.7%)(P< 0.01).Conclusion:The effect of rhEPO, 40000 u/w, on the anemia associated with chemotherapy in colorectal carcinoma was definitely positive.